Addiction

As Research into Pain Accelerates, a Newly Recognized Type of Pain Comes to the Forefront – Tonix Targets it with FDA-Fast Track-Designated TNX-102 SL

CHATHAM, NJ / ACCESSWIRE / September 4, 2024 / This post was written and published as a collaboration between the…

1 year ago

Revolutionary Hypnotherapy Technique Emerges as the #1 Method to Quit Nicotine – Changing the Game in Behavioral Health

SAN FRANCISCO, CA / ACCESSWIRE / September 3, 2024 / In a groundbreaking development for those struggling with nicotine addiction,…

1 year ago

Leading Computational Scientist and Oncology Researcher Elana Fertig, PhD, Appointed New Director of Institute for Genome Sciences

Internationally-recognized for her work in developing predictive models for drug resistance in cancer treatment BALTIMORE, Aug. 30, 2024 /PRNewswire/ --…

1 year ago

RELEASE RECOVERY ACQUIRES LEADING MEN’S PERSONAL WELLBEING PLATFORM MANUAL TO EXPAND NATIONAL REACH AND OFFER MORE COMPREHENSIVE SERVICES

New Entity Combines Release Recovery's Best in Class Behavioral Health Care Services to Include MANUAL's Technology Platform and College Campus…

1 year ago

Awakn Announces Key Progress in Its Aminoindane Pre-Clinical Program

Toronto, Ontario--(Newsfile Corp. - August 28, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF), a clinical-stage biotechnology company…

1 year ago

Mahajan Therapeutics Unveils Brand Refresh

LEWISVILLE, Texas, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Mahajan Therapeutics, Ohio’s premier provider of mental health and addiction health services,…

1 year ago

PRIMEFOCUS AND MARSHALL HEALTH NETWORK COLLABORATE ON NEW HEALTHCARE SERVICE SOLUTION

HUNTINGTON, W.Va., Aug. 26, 2024  /PRNewswire/ -- Marshall Health Network, Inc., a leading West Virginia-based academic health system, announces a new…

1 year ago

KindlyMD(TM) Appoints Nancy Pratt as Behavioral Health Program Director

Ms. Pratt, a seasoned mental health counselor with extensive academic and practical experience, will enhance the Company's Complete Care and…

1 year ago

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 CATALYST Study of TNX-1300 for the Treatment of Cocaine Intoxication

CATALYST is a Phase 2 single-blind, placebo-controlled, proof-of-concept study in patients presenting to the emergency department More than 27,569 individuals…

1 year ago